Role of Ferroptosis in Fibrotic Diseases

Zhou, Jian; Yuan, Tao; Wang, Rurong; Li, Xuehan

doi:10.2147/jir.s358470

Cited by 22 publications

(7 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 510 Evidence has shown that ferroptosis is involved in the pathogenesis of kidney fibrosis. 432 , 487 , 511 – 516 A recent study also showed the role of epigenetic regulation of ferroptosis by deacetylation in kidney fibrosis. Sirtuin 1-mediated p53 deacetylation was found to attenuate calcium oxalate deposition-induced renal fibrosis by suppressing ferroptosis.…”

Section: Epigenetic and Posttranslational Modifications Regulating Fe...mentioning

confidence: 97%

Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases

Wang,

Hu,

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

Ferroptosis, a unique modality of cell death with mechanistic and morphological differences from other cell death modes, plays a pivotal role in regulating tumorigenesis and offers a new opportunity for modulating anticancer drug resistance. Aberrant epigenetic modifications and posttranslational modifications (PTMs) promote anticancer drug resistance, cancer progression, and metastasis. Accumulating studies indicate that epigenetic modifications can transcriptionally and translationally determine cancer cell vulnerability to ferroptosis and that ferroptosis functions as a driver in nervous system diseases (NSDs), cardiovascular diseases (CVDs), liver diseases, lung diseases, and kidney diseases. In this review, we first summarize the core molecular mechanisms of ferroptosis. Then, the roles of epigenetic processes, including histone PTMs, DNA methylation, and noncoding RNA regulation and PTMs, such as phosphorylation, ubiquitination, SUMOylation, acetylation, methylation, and ADP-ribosylation, are concisely discussed. The roles of epigenetic modifications and PTMs in ferroptosis regulation in the genesis of diseases, including cancers, NSD, CVDs, liver diseases, lung diseases, and kidney diseases, as well as the application of epigenetic and PTM modulators in the therapy of these diseases, are then discussed in detail. Elucidating the mechanisms of ferroptosis regulation mediated by epigenetic modifications and PTMs in cancer and other diseases will facilitate the development of promising combination therapeutic regimens containing epigenetic or PTM-targeting agents and ferroptosis inducers that can be used to overcome chemotherapeutic resistance in cancer and could be used to prevent other diseases. In addition, these mechanisms highlight potential therapeutic approaches to overcome chemoresistance in cancer or halt the genesis of other diseases.

show abstract

Section: Epigenetic and Posttranslational Modifications Regulating Fe...mentioning

confidence: 97%

Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases

Wang,

Hu,

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…It is well-established that specific types of RCD, including ferroptosis, can activate the immune system and initiate an inflammatory reaction [156]. Therefore, ferroptosis induction has been implicated in the pathogenesis of fibrogenesis in diverse organs, including the liver, kidney, myocardium, gastrointestinal system, salivary glands, pancreas, prostate, and lung [157][158][159]. The ferroptotic mechanisms underlying the development of fibrosis in these organs have been thoroughly revised elsewhere [157,159].…”

Section: Adverse Events Of Ferroptosis Inducers As Radiosensitizersmentioning

confidence: 99%

“…Therefore, ferroptosis induction has been implicated in the pathogenesis of fibrogenesis in diverse organs, including the liver, kidney, myocardium, gastrointestinal system, salivary glands, pancreas, prostate, and lung [157][158][159]. The ferroptotic mechanisms underlying the development of fibrosis in these organs have been thoroughly revised elsewhere [157,159]. Albeit ferroptosis induction has been extensively linked to fibrosis, knowledge about the role of ferroptosis in RIF and acute tissue toxicity is still limited.…”

Section: Adverse Events Of Ferroptosis Inducers As Radiosensitizersmentioning

confidence: 99%

Ferroptosis: Frenemy of Radiotherapy

Kerkhove,

Geirnaert,

Dufait

et al. 2024

IJMS

View full text Add to dashboard Cite

Recently, it was established that ferroptosis, a type of iron-dependent regulated cell death, plays a prominent role in radiotherapy-triggered cell death. Accordingly, ferroptosis inducers attracted a lot of interest as potential radio-synergizing drugs, ultimately enhancing radioresponses and patient outcomes. Nevertheless, the tumor microenvironment seems to have a major impact on ferroptosis induction. The influence of hypoxic conditions is an area of interest, as it remains the principal hurdle in the field of radiotherapy. In this review, we focus on the implications of hypoxic conditions on ferroptosis, contemplating the plausibility of using ferroptosis inducers as clinical radiosensitizers. Furthermore, we dive into the prospects of drug repurposing in the domain of ferroptosis inducers and radiosensitizers. Lastly, the potential adverse effects of ferroptosis inducers on normal tissue were discussed in detail. This review will provide an important framework for subsequent ferroptosis research, ascertaining the feasibility of ferroptosis inducers as clinical radiosensitizers.

show abstract

“…A potential strategy to overcome this challenge is targeting common mechanisms and core pathways with central pathophysiological relevance in different pathological alterations in AKI to CKD [50]. Ferroptosis plays a vital role in regulating various cellular processes, such as inflammation [51], mitochondrial dysfunction [52], fibrosis [53], and renal cell regeneration [54], and has been considered a promising therapeutic target in the progression of AKI to CKD.…”

Section: The Role Of Ferroptosis In the Pathogenesis Of Aki To Ckd Pr...mentioning

confidence: 99%

The Road from AKI to CKD: Molecular Mechanisms and Therapeutic Targets of Ferroptosis

et al. 2023

View full text Add to dashboard Cite

Acute kidney injury (AKI) is a prevalent pathological condition that is characterized by a precipitous decline in renal function. In recent years, a growing body of studies have demonstrated that renal maladaptation following AKI results in chronic kidney disease (CKD). Therefore, targeting the transition of AKI to CKD displays excellent therapeutic potential. However, the mechanism of AKI to CKD is mediated by multifactor, and there is still a lack of effective treatments. Ferroptosis, a novel nonapoptotic form of cell death, is believed to have a role in the AKI to CKD progression. In this study, we retrospectively examined the history and characteristics of ferroptosis, summarized ferroptosis’s research progress in AKI and CKD, and discussed how ferroptosis participates in regulating the pathological mechanism in the progression of AKI to CKD. Furthermore, we highlighted the limitations of present research and projected the future evolution of ferroptosis. We hope this work will provide clues for further studies of ferroptosis in AKI to CKD and contribute to the study of effective therapeutic targets to prevent the progression of kidney diseases.

show abstract

Role of Ferroptosis in Fibrotic Diseases

Cited by 22 publications

References 137 publications

Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases

Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases

Ferroptosis: Frenemy of Radiotherapy

The Road from AKI to CKD: Molecular Mechanisms and Therapeutic Targets of Ferroptosis

Contact Info

Product

Resources

About